Association of lipid metabolism-related gene promoter methylation with risk of coronary artery disease

Wei Li¹ · Yongyi Wang¹ · Ritai Huang¹ · Feng Lian¹ · Genxing Xu¹ · Weijun Wang¹ · Song Xue¹

Received: 8 February 2022 / Accepted: 12 July 2022 / Published online: 8 August 2022
© The Author(s), under exclusive licence to Springer Nature B.V. 2022

Abstract
Background: Coronary artery disease (CAD) is a complex disease that is influenced by environmental and genetic factors. Lipid levels are regarded as a major risk factor for CAD, and epigenetic mechanisms might be involved in the regulation of CAD development. This study was designed to investigate the association between the DNA methylation status of 8 lipid metabolism-related genes and the risk of CAD in the Chinese Han population.

Methods: A total of 260 individuals were sampled in this study, including 120 CAD cases and 140 normal healthy controls. DNA methylation status was tested via targeted bisulfite sequencing.

Results: The results indicated a significant association between hypomethylation of the APOC3, CETP and APOC1 gene promoters and the risk of CAD. Individuals with higher methylation levels of the APOA5 and LIPC gene promoters had increased risks for CAD. In addition, ANGPTL4 methylation level was significantly associated with CAD in males but not females. There were no significant differences in the methylation levels of the APOB and PCSK9 gene promoters between CAD patients and controls.

Conclusions: The methylation status of the APOC3, APOA5, LIPC, CETP and APOC1 gene promoters may be associated with the development of CAD.

Keywords Coronary artery disease · Lipid metabolism · Methylation

Introduction
Coronary artery disease (CAD) is a common chronic inflammatory disease that has been recognized as the leading cause of death worldwide [1]. In China, it is estimated that 700,000 people died from CAD every year [2]. Blood lipid levels, including triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and serum total cholesterol (TC) levels, have been identified as important independent risk factors for CAD [3]. Recent advances have started to reveal the genetic architecture of CAD and have shown that genetic variants and epigenetic regulation of lipid metabolism-related genes also contribute to CAD etiology [4–6].

DNA methylation is a biological process in which gene expression is regulated by the recruitment of proteins involved in gene repression or by inhibition of the binding of transcription factors to DNA without changing the DNA sequence. Aberrant promoter hypermethylation and hypomethylation may be associated with risks of various diseases, including cardiovascular, cancer and metabolic diseases [7–9]. Several previous studies have revealed that the methylation signatures of critical genes may play a role in CAD development [4–6].

In this study, we aimed to investigate the association of the methylation status of 8 lipid metabolism-related genes (ANGPTL4, APOC3, APOA5, APOB, LIPC, CETP, PCSK9 and APOC1) with the risk of CAD development in the Chinese Han population.

Materials and methods
Study population.
The participants in this study were recruited from Shanghai Renji Hospital between 2018 and 2020. A total of 120 CAD patients (88 male and 32 female) and 140 non-CAD controls (93 male and 47 female) were included in this study. The criterion for CAD diagnosis was at least one of the major segments of the coronary arteries (right coronary, left circumflex, or left anterior descending artery) with at least 50% organic stenosis based on coronary angiography. All unaffected controls were determined to be free of CAD. All participants were genetically unrelated Chinese Han individuals from Shanghai. This study was approved by the Medical Ethics Committee of Renji Hospital affiliated with the Shanghai Jiaotong University School of Medicine and compliant with the principles set forth by the Declaration of Helsinki. Written informed consent was obtained from all subjects. Blood samples (5 ml) were collected from the participants into EDTA tubes and then stored at −80 °C for further use.

DNA extraction, bisulfite conversion and targeted bisulfite sequencing.

Genomic DNA was extracted from whole blood with a Tiangen DNA extraction kit (Tiangen Ltd., Beijing, China) according to the manufacturer’s instructions. DNA quality and concentration were analyzed using electrophoresis and a NanoDrop spectrophotometer (NanoDrop Technologies, Houston, TX, USA). Bisulfite conversion of 200 ng genomic DNA was performed by the EZ DNA Methylation-Gold Kit (Zymo Research, Irvine, CA, USA) according to the manufacturer's standard protocol. For each gene, PCR primers were designed specifically for bisulfite-converted DNA using MethPrimer [10]. PCR primers were synthesized by Shanghai Free Biotechnology Co., Ltd. (Shanghai, China). Multiplex PCR of target CpG regions was performed, and the products were sequenced with Illumina NovaSeq sequencing instruments (Novogene, Beijing, China). A mean sequencing depth of >500X was achieved for all samples. CpG sites were named according to their relative distance (in bp) to the transcriptional start site (TSS) (with negative distances upstream from the TSS). The methylation level of each CpG site was calculated as the percentage of the methylated cytosines over the total tested cytosines. The average methylation level was calculated using the methylation levels of all measured CpG sites within the gene.

Statistical analysis

Statistical analyses were performed using SPSS version 21.0 (SPSS Inc., Chicago, IL, USA) and GraphPad Prism 5 software (GraphPad Software Inc., San Diego, CA, USA). The correlation between DNA methylation and CAD was assessed using an independent sample t test and expressed as the mean ± standard deviation (SD). Both the average gene methylation data and the methylation data for the individual CpG loci were analyzed. Stratified analyses based on sex were carried out. A P value < 0.05 was considered statistically significant.

Results

A total of 120 CAD patients and 140 healthy controls were recruited for this study. Targeted bisulfite sequencing was used to assess a total of 98 CpG sites in 8 lipid metabolism-related gene (ANGPTL4, APOC3, APOA5, APOB, LIPC, CETP, PCSK9 and APOC1) promoters. The methylation levels of each CpG site were compared between patients and healthy controls (Fig. 1). The methylation levels of 14 sites were significantly higher in the case group than in the control group, while the methylation levels of 37 sites were significantly lower in the case group than in the control group (supplementary Table 1).

The mean methylation level of each gene was calculated (Table 1). As shown in Table 1, significantly decreased
methylolation statuses of the APOC3, APOA5, LIPC, CETP and APOC1 gene promoters were observed between CAD patients and healthy controls. DNA methylation could serve as a biomarker for predicting the risk of CAD [11–13].

APOC3 encodes a protein component of TG-rich lipoproteins (TRLs) and plays a role in promoting the hepatic secretion of TRLs. APOC3 is an inhibitor of lipoprotein lipase (LPL) enzyme activity and prevents TRL clearance [14, 15]. Loss-of-function APOC3 mutations were associated with low plasma TG levels and reduced risk of cardiovascular disease [16, 17]. Genetic variation in the promoter region of the APOC3 gene was associated with increased risks of hypertriglyceridemia, metabolic syndrome and CAD [18–20]. Overexpression of the APOC3 gene in transgenic animals induces severe hypertriglyceridemia, while APOC3 gene deletion results in hypotriglyceridemia [21–24]. In this study, the APOC3 gene was hypomethylated in CAD patients. The methylation level of CpG-119 in the APOC3 gene promoter was significantly lower in the CAD group than in the control group (13.5% vs. 24.5%) and might lead to higher gene expression.

The APOC1 gene encodes a member of the apolipoprotein C1 family and resides within the APOE/APOC1/APOC2 gene cluster. This gene is predominantly expressed in the liver, lung, skin, spleen, adipose tissue, and brain [25]. APOC1 plays an important role in high-density lipoprotein (HDL) and very-low-density lipoprotein (VLDL) metabolism. APOC1 is a very potent and highly selective inhibitor of cholesteryl ester transfer protein (CETP) in plasma [26, 27]. Transgenic analysis revealed that increased expression

**Table 1** Mean methylation levels (%) of candidate genes in cases and controls

| Gene    | CAD                  | Non-CAD              | P value     |
|---------|----------------------|----------------------|-------------|
| ANGPTL4 | 57.42±3.72           | 56.93±2.68           | 0.233       |
| APOC3   | 66.75±3.14           | 71.84±1.99           | **1.17E-26**|
| APOA5   | 85.07±2.03           | 84.5±1.76            | **0.022**   |
| APOB    | 27.78±7.06           | 28.77±6.24           | 0.258       |
| LIPC    | 61.37±7.07           | 54.35±6.11           | **1.59E-15**|
| CETP    | 48.7±4.58            | 62.13±4.69           | **1.33E-49**|
| PCSK9   | 21.46±2.48           | 21.33±1.86           | 0.672       |
| APOC1   | 55.95±3.94           | 59.05±2.41           | **8.40E-12**|

Methylation levels (%) are reported as the means ± SDs, and P values less than 0.05 are shown in bold.

Furthermore, subgroup analyses based on sex were carried out, which demonstrated that the results for APOC3, LIPC, CETP and APOC1 remained significant in both males and females, those for while APOA5 remained significant only in males (Table 2). ANGPTL4 was hypermethylated in males but not in females. No significant association was identified for APOB or PCSK9 methylation in the stratified analysis.

**Discussion**

CAD is a complex disease that is influenced by environmental, biochemical, and genetic risk factors. Lipoprotein metabolism disorder is a causal risk factor for cardiovascular diseases in the general population. DNA methylation, the most widely studied epigenetic mechanism, plays an important role in the etiology of human disease. Recent studies revealed that DNA methylation changes in gene promoters might be implicated in the development of CAD. In this study, we investigated the methylation status of a subset of lipid metabolism-related genes in CAD patients and control subjects in the Chinese Han population via targeted bisulfite sequencing.

The results support the hypothesis that epigenetic changes within lipid metabolism-related genes might account for blood lipid profile variability and could be a molecular mechanism explaining the pathogenesis of CAD. Different methylation statuses of the APOC3, APOA5, LIPC, CETP and APOC1 gene promoters were observed between CAD patients and healthy controls. DNA methylation could serve as a biomarker for predicting the risk of CAD [11–13].

**Table 2** Mean methylation levels (%) of candidate genes in males and females

| Gene    | CAD (Males) | Non-CAD (Males) | P value | CAD (Females) | Non-CAD (Females) | P value |
|---------|-------------|----------------|---------|---------------|------------------|---------|
| ANGPTL4 | 57.76±3.98  | 56.61±2.59     | **0.024**| 56.47±2.71    | 57.55±2.76       | 0.089   |
| APOC3   | 66.68±3.28  | 71.67±1.98     | **1.40E-18**| 66.96±2.79    | 72.19±1.99       | **1.62E-12**|
| APOA5   | 85.16±1.98  | 84.47±1.59     | **0.015**| 84.84±2.21    | 84.55±2.07       | 0.587   |
| APOB    | 27.68±7.51  | 28.1±6.14      | 0.697   | 28.04±5.89    | 30.11±6.3        | 0.168   |
| LIPC    | 62.05±6.69  | 54.01±5.78     | **5.23E-15**| 59.55±7.82    | 55.02±6.74       | **0.008**|
| CETP    | 48.3±4.38   | 61.5±4.36      | **1.44E-37**| 49.9±4.99     | 63.54±5.13       | **4.25E-14**|
| PCSK9   | 21.51±2.32  | 21.09±1.94     | 0.252   | 21.35±2.89    | 21.8±1.58        | 0.488   |
| APOC1   | 55.74±4.09  | 58.46±2.28     | **3.51E-07**| 56.54±3.48    | 60.23±2.25       | **7.93E-06**|

Methylation levels (%) are reported as the means ± SDs, and P values less than 0.05 are shown in bold.
of APOC1 inhibits the hepatic uptake of lipoproteins and results in combined hyperlipidemia [28–30]. In this study, 12 CpG sites in APOC1 were analyzed, and 11 CpG sites from −38 to +164 were hypomethylated in CAD patients. The methylation level of CpG-50 was not significantly different between the case and control groups.

CETP mediates the transfer of cholesteryl ester from HDL to other lipoproteins and promotes the formation of TG-rich and CE-poor HDL particles. Genetic variation in CETP has been reported to be associated with HDL-C levels [28–33]. CETP deficiency was associated with slow progression of CAD, high HDL-C level, low HDL-TG levels and a larger HDL particle size [34, 35]. CETP inhibitors effectively reduce LDL-C levels and increase HDL-C levels and may be effective in reducing atherosclerosis and cardiovascular events [36]. In this study, 9 of 10 CpG sites from −94 to +140 in the CETP gene were hypomethylated in CAD patients. The methylation level of CpG+269 did not differ significantly between the case and control groups.

LIPC encodes hepatic triglyceride lipase, which participates in the hydrolysis of TGs and phospholipids and is mainly expressed in and secreted from the liver. Variants in the promoter region of LIPC were reported to be correlated with high HDL-C levels [37, 38]. It has been reported that in familial hypercholesterolemia, subjects with a previous history of CAD had higher LIPC DNA methylation levels than those without a CAD history [39]. Our study revealed that 3 of 4 CpG sites from −40 to +44 in the LIPC gene were hypermethylated in CAD patients. The methylation level of CpG+131 did not differ significantly between the case and control groups.

The APOA5 gene plays an important role in the regulation of blood triglyceride levels and is regarded as a major risk factor for coronary heart disease. Genome-wide methylation analysis revealed that APOA5 was hypomethylated in children with obesity [40]. APOA5 hypomethylation is also involved in aortic valve stenosis (AVS) [41]. Genetic variation in the APOA5 gene was associated with the levels of plasma lipids and an increased risk of cardiovascular disease [42, 43]. The mean methylation level of the APOA5 gene was relatively high in CAD patients compared with the control group. However, CpG −50 and CpG+32 were hypermethylated, while CpG −343 and CpG −186 were hypomethylated.

DNA methylation affects gene expression and regulates lipid metabolism. However, the cause of methylation variation is still poorly understood. DNA methylation signature was previously shown to be partially inherited. The methylation pattern can be affected by nearby single nucleotide polymorphisms (SNPs) [44, 45]. It has been revealed that the interaction of genetic and epigenetic variation contributes to the development of complex diseases [46]. In addition to genetic variants, environmental and lifestyle modifications are also considered to be potential causes of DNA methylation diversity [47–49]. Previous reports showed that a high-fat diet introduced DNA methylation changes in skeletal muscle and subcutaneous adipose tissue. Consumption of a high-fat diet is also associated with an increased risk of metabolic diseases [50, 51]. Hahn found that dietary restriction remodels DNA methylation patterns and gene expression, particularly of genes involved in lipid metabolism [52]. In addition, physical activity, smoking and drinking also induce DNA methylation variations [53–56].

In conclusion, targeted bisulfite sequencing was used to assess the methylation status of 8 lipid metabolism-related candidate genes in patients diagnosed with CAD and control subjects without CAD. We revealed that the methylation levels of the APOC3, CETP and APOC1 gene promoters were lower in the CAD group than in the control group. The methylation levels of the APOA5 and LIPC gene promoters were higher in the CAD group than in the control group. Our findings support the hypothesis that DNA methylation of lipid-related genes plays a role in the development of CAD and provide some new insight for the prevention and treatment of CAD. However, there are some limitations to this study. The expression levels of the target genes were not investigated, so we could not determine whether promoter methylation affects gene expression. Moreover, variations in the gene regions and DNA methylation might have dual effects on disease development. Further study of a larger sample with expression and genotyping data is needed to confirm our results.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s11033-022-07789-0.

Acknowledgements This project was funded by the Shanghai Science and Technology Development Foundation (SY20221RUE01). We also thank Hu Liu from Shanghai Lehao Bio-Science Company for his technical support in gene sequencing.

References
1. Roger VL, Go AS, Lloyd-Jones DM et al (2011) Heart disease and stroke statistics–2011 update: a report from the American Heart Association. Circulation 123(4):e18–e209
2. Wang F, Xu CQ, He Q et al (2011) Genome-wide association identifies a susceptibility locus for coronary artery disease in the Chinese Han population. Nat Genet 43(4):345–349
3. Foody J, Yong H, Ji L et al (2013) Unique and Varied Contributions of Traditional CVD Risk Factors: A Systematic Literature Review of CAD Risk Factors in China. Clin Med Insights Cardiol. ; 2013(7):59–86
4. Duan L, Liu C, Hu J et al (2018) Epigenetic mechanisms in coronary artery disease: The current state and prospects. Trends Cardiovasc Med 28(5):311–319
5. Pjanić M, Miller CL, Wirka R et al (2016) Genetics and Genom- 
ic of Coronary Artery Disease. Curr Cardiol Rep 18(10):102
6. Musunuru K, Kathiresan S (2019) Genetics of Common, Com- 
plex Coronary Artery Disease. Cell 177(1):132–145
7. Ghaznavi H, Mahmodi K, Soltanpour MS (2018) A preliminary 
study of the association between the ABCA1 gene promoter DNA 
methylation and coronary artery disease risk. Mol Biology Res 
Commun 7(2):59–65
8. Su J, Li J, Yu Q et al (2019) Association of PON1 gene pro- 
moter DNA methylation with the risk of Clopidogrel resis- 
tance in patients with coronary artery disease. J Clin Lab Anal 
33(5):e22867
9. Zhuang J, Peng W, Li H et al (2012) Methylation of p15INK4b 
and Expression of ANRIL on Chromosome 9p21 Are Associated 
with Coronary Artery Disease. PLoS ONE 7(10):e47193
10. Li LC, Dahiya R, Methprimer (2002) Designing Primers for 
Methylation PCRs. Bioinformatics 18(11):1427–1431
11. Agha G et al “Blood Leukocyte DNA Methylation Predicts Risk 
of Future Myocardial Infarction and Coronary Heart Disease.” 
Circulation 140(8.2019):645–657
12. Zhao X et al (2022) “F2RL3 Methylation in the Peripheral Blood 
as a Potential Marker for the Detection of Coronary Heart 
Disease: A Case-Control Study.” Front Genet. 24:833923
13. Xia Y, Brewer A, Bell JT “DNA methylation signatures of inci- 
dent coronary heart disease: findings from epigenome-wide asso- 
ciation studies.”Clinical Epigenetics13.1(2021):1–16
14. Taskinen MR, Packard CJ, Boren J (2019) Emerging Evidence 
that Apo-C-III Inhibitors Provide Novel Options to Reduce the 
Residual CVD. Curr Atheroscler Rep 21(8):27
15. Akoumianakis I, Zvintzou E, Kypreos K et al (2021) ANGPT3 
and Apolipoprotein C-III as Novel Lipid-Lowering Targets. Curr 
Atheroscler Rep 23(5):20
16. Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG et al (2014) 
Loss-of-Function Mutations in APOC3 and Risk of Ischemic 
Vascular Disease. N Engl J Med 371(1):32–41
17. Crosby J, Peloso GM, Auer PL et al (2014) Loss-of-function muta-
 tions in APOC3, triglycerides, and coronary disease. N Engl 
J Med 371(1):22–31
18. Li WW, Dammerman MM, Smith J et al (1996) Common genetic 
variation in the promoter of the human apo CII gene abolishes 
regulation by insulin and may contribute to hypertriglyceridemia. 
J Clin Invest 96(6):2601–2605
19. Pollex RL, Ban MR, Young TK et al (2007) Association between 
the –455T > C promoter polymorphism of the APOC3 gene and 
the metabolic syndrome in a multi-ethnic sample. BMC Med 
Genet 8(80):1471–2350
20. Olivieri O, Stranieri C, Bassi A et al (2002) ApoC-III gene poly-
morphisms and risk of coronary artery disease[J]. J Lipid Res 
43(9):1450–1457
21. Jong MC, Rensen PC, Dahlmans VE et al (2001) Apolipoprotein 
C-III deficiency accelerates triglyceride hydrolysis by lipo-
protein lipase in wild-type and apoE knockout mice. J Lipid Res 
42(10):1578–1585
22. Yan H, Niimi M, Matsushita F et al (2020) Apolipoprotein CIII 
Deficiency Protects Against Atherosclerosis in Knockout Rab-
bits. Arteriosclerosis Thrombosis and Vascular Biology.; 40(9)
23. Ding Y, Wang Y, Hong Z et al (2011) Hypertriglyceridemia and 
delayed clearance of fat load in transgenic rabbits expressing 
human apolipoprotein CIII. Transgenic Res 20(4):867
24. Ito Y, Azrolan N, O’Connell A et al (1990) Hypertriglyceridemia 
as a result of human apo CIII gene expression in transgenic mice. 
Science 249(4970):790–793
25. Lauer SJ, Walker D, Elshourbagy NA et al (1988) Two copies 
of the human apoprotein C-I gene are linked closely to the 
apolipoprotein E gene. J Biol Chem 263(15):7277–7286
26. Gautier T, Masson D, Jong MC et al (2002) Apolipoprotein C1 
Deficiency Markedly Augments Plasma Lipoprotein Changes 
Mediated by Human Cholesteryl Ester Transfer Protein (CETP) 
in CETP Transgenic/ApoC1-knockout Mice. J Biol Chem 
277(35):31354
27. Gautier T, Masson D, de Barros JP et al (2000) Human Apoli-
oprotein C-I Accounts for the Ability of Plasma High Density 
Lipoproteins to Inhibit the Cholesteryl Ester Transfer Protein 
Activity. J Biol Chem 275(48):37504–37509
28. Shachter NS, Ebara T, Ramakrishnan R et al (1996) Combined 
hypertriglyceridemia in transgenic mice overexpressing human apoli-
oprotein C1. J Clin Invest 98(3):846–855
29. Jong MC, Dahlmans VE, Gorp P et al (1996) In the absence of 
the low density lipoprotein receptor, human apolipoprotein C1 
overexpression in transgenic mice inhibits the hepatic uptake of 
very low density lipoproteins via a receptor-associated protein-
sensitive pathway. J Clin Investig 98(10):2259–2267
30. Berbee JF, Hoogt CC, Sundararaman D et al (2005) Severe hyper-
triglyceridemia in human APOC1 transgenic mice is caused by 
apoC-I-induced inhibition of LPL. J Lipid Res 46(2):297–306
31. Takahashi K, Jiang XC, Sakai N et al (1993) A missense mutation 
in the cholesteryl ester transfer protein gene with possible domi-
nant effects on plasma high density lipoproteins. J Clin Invest 
92(4):2060–2064
32. Arai T, Yamashita S, Sakai N et al (1996) A novel nonsense muta-
tion (G181X) in the human cholesteryl ester transfer protein gene 
in Japanese hyperalphalipoproteinemic subjects. J Lipid Res 
37(10):2145
33. Boekholdt SM, Thompson JF (2003) Natural genetic variation as 
a tool in understanding the role of CETP in lipid levels and dis-
 ease. J Lipid Res 44(6):1080–1093
34. Inazu A, Jiang XC, Haraki T et al (1994) Genetic cholesteryl ester 
transfer protein deficiency caused by two prevalent mutations as a 
major determinant of increased levels of high density lipoprotein 
cholesterol. J Clin Invest 94(5):1872–1882
35. Arai T, Tsukada T, Murase T et al (2000) Particle size analysis of 
high density lipoproteins in patients with genetic cholesteryl ester 
transfer protein deficiency. Clin Chim Acta 313(1–2):103–117
36. Mabuchi H, Nohara A, Inazu A (2014) Cholesteryl Ester Transfer 
protein (CETP) Deficiency and CETP Inhibitors. Molecules & 
Cells & Metabolism. (8):3858–3863
37. Hodoğlugil U, Williamson DW, Mahley RW (2010) Polymor-
phisms in the hepatic lipase gene affect plasma HDL-cholesterol 
levels in a Turkish population. J Lipid Res 51(2):422
38. Guay SP, Brisson D, Lamarche B et al (2014) Epipolymorphisms 
within lipoprotein genes contribute independently to plasma 
lipid levels in familial hypercholesterolemia[J]. Epigenetics 
9(5):718–729
39. Li Y, Zhou Y, Zhu L et al (2018) Genome-wide analysis reveals 
that altered methylation in specific CpG loci is associated with 
childhood obesity. J Cell Biochem 119(9):7490–7497
40. Radhakrishna U, Alpayrak S, Alpay-Savasan Z et al (2016) Genome-
Wide DNA Methylation Analysis and Epigenetic Varia-
tions Associated with Congenital Aortic Valve Stenosis (A VS). 
BMC Med Genet 11:120
44. Kerkel K et al (2008) “Genomic surveys by methylation-sensitive SNP analysis identify sequence-dependent allele-specific DNA methylation.” Nat Genet 40:904
45. Lu T et al “Whole-genome bisulfite sequencing in systemic sclerosis provides novel targets to understand disease pathogenesis.” BMC Medical Genomics 12.1(2019):1–12
46. Dayeh TA et al “Identification of CpG-SNPs associated with type 2 diabetes and differential DNA methylation in human pancreatic islets.” Diabetologia 56.5(2013):1036–1046
47. Zhou D et al “High Fat Diet and Exercise Lead to a Disrupted and Pathogenic DNA Methylome in Mouse Liver.” Epigenetics 12.1(2016):00–00
48. Martin EM, Fry RC (2018). “Environmental Influences on the Epigenome: Exposure-Associated DNA Methylation in Human Populations.” Annual Review of Public Health 39.1
49. Suderman M et al (2014) “Childhood abuse is associated with methylation of multiple loci in adult DNA.” BMC Medical Genomics, 7.1(2014-03-11) 7.1:13
50. Gillberg L et al “PPARGC1A DNA methylation in subcutaneous adipose tissue in low birth weight subjects—impact of 5 days of high-fat overfeeding.” Metabolism-clinical & Experimental 63.2(2014):263–271
51. Jacobsen SC et al (2012) Effects of short-term high-fat overfeeding on genome-wide DNA methylation in the skeletal muscle of healthy young men. Diabetologia 55:3341–3349
52. Hahn O et al (2017) Dietary restriction protects from age-associated DNA methylation and induces epigenetic reprogramming of lipid metabolism. Genome Biol 18(1):56
53. Romain, Barrès et al (2012) “Acute exercise remolds promoter methylation in human skeletal muscle.” Cell Metabolism 153:405–411
54. Rönn T et al (2013) A Six Months Exercise Intervention Influences the Genome-wide DNA Methylation Pattern in Human Adipose Tissue. PLoS Genet 9:e1003572
55. Dogan MV et al “The effect of smoking on DNA methylation of peripheral blood mononuclear cells from African American women.” BMC Genomics, 15.1(2014-02-22) 15.1(2014):151
56. Philibert RA et al (2014) “A pilot examination of the genome-wide DNA methylation signatures of subjects entering and exiting short-term alcohol dependence treatment programs.” Epigenetics 9:1212–1219

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.